Effect of phosphodiesterase-type 5 inhibitors on erectile function: an overview of systematic reviews and meta-analyses
Introduction Phosphodiesterase-type 5 inhibitors (PDE5i) are the recommended first-line treatment for erectile dysfunction. Previous systematic reviews and meta-analyses suggest that they are a safe and effective option in many patient groups. Similarly, PDE5i may be effective as part of combination...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2021-08-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/11/8/e047396.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846136586541989888 |
|---|---|
| author | Ioannis Mykoniatis Anna-Bettina Haidich Nikolaos Pyrgidis Maria Tirta Persefoni Talimtzi Dimitrios Kalyvianakis Andreas Ouranidis Dimitrios Hatzichristou |
| author_facet | Ioannis Mykoniatis Anna-Bettina Haidich Nikolaos Pyrgidis Maria Tirta Persefoni Talimtzi Dimitrios Kalyvianakis Andreas Ouranidis Dimitrios Hatzichristou |
| author_sort | Ioannis Mykoniatis |
| collection | DOAJ |
| description | Introduction Phosphodiesterase-type 5 inhibitors (PDE5i) are the recommended first-line treatment for erectile dysfunction. Previous systematic reviews and meta-analyses suggest that they are a safe and effective option in many patient groups. Similarly, PDE5i may be effective as part of combination therapy in non-responders to PDE5i. We will generate an overview of systematic reviews, meta-analyses and network meta-analyses aiming to summarise the available knowledge regarding the efficacy and safety of PDE5i in the general population and in multiple subgroups of patients.Methods and analysis This overview was designed in accordance with the PRIO-harms and Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols guidelines and its protocol was registered at PROSPERO. We will systematically search PubMed, Web of Science, Cochrane Library and Scopus databases from inception to November 2020 without any language restrictions. We will include systematic reviews or meta-analyses: (1) comparing the efficacy and safety of any dose of PDE5i with each other, with placebo or with other effective treatments for the management of erectile function; (2) exploring the use of any PDE5i alone or in combination with other treatment modalities in the general male population or in specific subgroups and (3) conducted with systematic procedures. Our overview will employ the AMSTAR 2 tool to evaluate the quality of the included studies and the Grading of Recommendations Assessment, Development and Evaluation approach to assess the strength of evidence for all outcomes. We will construct forest plots of risk estimates with the corresponding CI for all outcomes.Ethics and dissemination In this overview, we will undertake an extensive literature search in an attempt to evaluate the potential benefits and risks of treatment with one PDE5i versus another or versus placebo and provide recommendations for clinicians and policy-makers. No ethical approval is required.PROSPERO registration number CRD42020216754. |
| format | Article |
| id | doaj-art-0e2eb91587b04bd59559a1cddee2b819 |
| institution | Kabale University |
| issn | 2044-6055 |
| language | English |
| publishDate | 2021-08-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | BMJ Open |
| spelling | doaj-art-0e2eb91587b04bd59559a1cddee2b8192024-12-09T02:05:09ZengBMJ Publishing GroupBMJ Open2044-60552021-08-0111810.1136/bmjopen-2020-047396Effect of phosphodiesterase-type 5 inhibitors on erectile function: an overview of systematic reviews and meta-analysesIoannis Mykoniatis0Anna-Bettina Haidich1Nikolaos Pyrgidis2Maria Tirta3Persefoni Talimtzi4Dimitrios Kalyvianakis5Andreas Ouranidis6Dimitrios Hatzichristou7Institute for the Study of Urological Diseases, Thessaloniki, GreeceDepartment of Hygiene, Social-Preventive Medicine and Medical Statistics, Aristotle University of Thessaloniki Faculty of Health Sciences, Thessaloniki, Central Macedonia, GreeceInstitute for the Study of Urological Diseases, Thessaloniki, GreeceUrology Department, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, GreeceDepartment of Hygiene, Social-Preventive Medicine & Medical Statistics, Aristotle University of Thessaloniki, Thessaloniki, GreeceInstitute for the Study of Urological Diseases, Thessaloniki, GreeceDepartment of Chemical Engineering, Aristotle University of Thessaloniki, Thessaloniki, GreeceInstitute for the Study of Urological Diseases, Thessaloniki, GreeceIntroduction Phosphodiesterase-type 5 inhibitors (PDE5i) are the recommended first-line treatment for erectile dysfunction. Previous systematic reviews and meta-analyses suggest that they are a safe and effective option in many patient groups. Similarly, PDE5i may be effective as part of combination therapy in non-responders to PDE5i. We will generate an overview of systematic reviews, meta-analyses and network meta-analyses aiming to summarise the available knowledge regarding the efficacy and safety of PDE5i in the general population and in multiple subgroups of patients.Methods and analysis This overview was designed in accordance with the PRIO-harms and Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols guidelines and its protocol was registered at PROSPERO. We will systematically search PubMed, Web of Science, Cochrane Library and Scopus databases from inception to November 2020 without any language restrictions. We will include systematic reviews or meta-analyses: (1) comparing the efficacy and safety of any dose of PDE5i with each other, with placebo or with other effective treatments for the management of erectile function; (2) exploring the use of any PDE5i alone or in combination with other treatment modalities in the general male population or in specific subgroups and (3) conducted with systematic procedures. Our overview will employ the AMSTAR 2 tool to evaluate the quality of the included studies and the Grading of Recommendations Assessment, Development and Evaluation approach to assess the strength of evidence for all outcomes. We will construct forest plots of risk estimates with the corresponding CI for all outcomes.Ethics and dissemination In this overview, we will undertake an extensive literature search in an attempt to evaluate the potential benefits and risks of treatment with one PDE5i versus another or versus placebo and provide recommendations for clinicians and policy-makers. No ethical approval is required.PROSPERO registration number CRD42020216754.https://bmjopen.bmj.com/content/11/8/e047396.full |
| spellingShingle | Ioannis Mykoniatis Anna-Bettina Haidich Nikolaos Pyrgidis Maria Tirta Persefoni Talimtzi Dimitrios Kalyvianakis Andreas Ouranidis Dimitrios Hatzichristou Effect of phosphodiesterase-type 5 inhibitors on erectile function: an overview of systematic reviews and meta-analyses BMJ Open |
| title | Effect of phosphodiesterase-type 5 inhibitors on erectile function: an overview of systematic reviews and meta-analyses |
| title_full | Effect of phosphodiesterase-type 5 inhibitors on erectile function: an overview of systematic reviews and meta-analyses |
| title_fullStr | Effect of phosphodiesterase-type 5 inhibitors on erectile function: an overview of systematic reviews and meta-analyses |
| title_full_unstemmed | Effect of phosphodiesterase-type 5 inhibitors on erectile function: an overview of systematic reviews and meta-analyses |
| title_short | Effect of phosphodiesterase-type 5 inhibitors on erectile function: an overview of systematic reviews and meta-analyses |
| title_sort | effect of phosphodiesterase type 5 inhibitors on erectile function an overview of systematic reviews and meta analyses |
| url | https://bmjopen.bmj.com/content/11/8/e047396.full |
| work_keys_str_mv | AT ioannismykoniatis effectofphosphodiesterasetype5inhibitorsonerectilefunctionanoverviewofsystematicreviewsandmetaanalyses AT annabettinahaidich effectofphosphodiesterasetype5inhibitorsonerectilefunctionanoverviewofsystematicreviewsandmetaanalyses AT nikolaospyrgidis effectofphosphodiesterasetype5inhibitorsonerectilefunctionanoverviewofsystematicreviewsandmetaanalyses AT mariatirta effectofphosphodiesterasetype5inhibitorsonerectilefunctionanoverviewofsystematicreviewsandmetaanalyses AT persefonitalimtzi effectofphosphodiesterasetype5inhibitorsonerectilefunctionanoverviewofsystematicreviewsandmetaanalyses AT dimitrioskalyvianakis effectofphosphodiesterasetype5inhibitorsonerectilefunctionanoverviewofsystematicreviewsandmetaanalyses AT andreasouranidis effectofphosphodiesterasetype5inhibitorsonerectilefunctionanoverviewofsystematicreviewsandmetaanalyses AT dimitrioshatzichristou effectofphosphodiesterasetype5inhibitorsonerectilefunctionanoverviewofsystematicreviewsandmetaanalyses |